These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12654707)

  • 1. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism.
    Hornig B; Kohler C; Schlink D; Tatge H; Drexler H
    Hypertension; 2003 May; 41(5):1092-5. PubMed ID: 12654707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway.
    Brown NJ; Gainer JV; Murphey LJ; Vaughan DE
    Circulation; 2000 Oct; 102(18):2190-6. PubMed ID: 11056091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension.
    Ghiadoni L; Virdis A; Magagna A; Taddei S; Salvetti A
    Hypertension; 2000 Jan; 35(1 Pt 2):501-6. PubMed ID: 10642349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase.
    Hornig B; Landmesser U; Kohler C; Ahlersmann D; Spiekermann S; Christoph A; Tatge H; Drexler H
    Circulation; 2001 Feb; 103(6):799-805. PubMed ID: 11171786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure.
    Hornig B; Arakawa N; Haussmann D; Drexler H
    Circulation; 1998 Dec 22-29; 98(25):2842-8. PubMed ID: 9860785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans.
    Hornig B; Kohler C; Drexler H
    Circulation; 1997 Mar; 95(5):1115-8. PubMed ID: 9054837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AT1 receptor blockade prevents the decrease in conduit artery flow-mediated dilatation during NOS inhibition in humans.
    Bellien J; Iacob M; Eltchaninoff H; Bourkaib R; Thuillez C; Joannides R
    Clin Sci (Lond); 2007 Jun; 112(7):393-401. PubMed ID: 17125466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II type 1 receptor antagonism improves endothelial vasodilator function in L-NAME-induced hypertensive rats by a kinin-dependent mechanism.
    De Gennaro Colonna V; Fioretti S; Rigamonti A; Bonomo S; Manfredi B; Muller EE; Berti F; Rossoni G
    J Hypertens; 2006 Jan; 24(1):95-102. PubMed ID: 16331106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An AT1-receptor antagonist and an angiotensin-converting enzyme inhibitor protect against hypoxia-induced apoptosis in human aortic endothelial cells through upregulation of endothelial cell nitric oxide synthase activity.
    Matsumoto N; Manabe H; Ochiai J; Fujita N; Takagi T; Uemura M; Naito Y; Yoshida N; Oka S; Yoshikawa T
    Shock; 2003 Jun; 19(6):547-52. PubMed ID: 12785010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease.
    Perrone-Filardi P; Corrado L; Brevetti G; Silvestro A; Dellegrottaglie S; Cafiero M; Caiazzo G; Petretta A; Maglione A; Monda C; Guerra G; Marzano A; Cesarano P; Gargiulo P; Chiariello M
    J Clin Hypertens (Greenwich); 2009 May; 11(5):260-5. PubMed ID: 19534023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V; Rigamonti A; Fioretti S; Bonomo S; Manfredi B; Ferrario P; Bianchi M; Berti F; Muller EE; Rossoni G
    Eur J Pharmacol; 2005 Jun; 516(3):253-9. PubMed ID: 15963975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardioprotective effect of angiotensin-converting enzyme inhibition against hypoxia/reoxygenation injury in cultured rat cardiac myocytes.
    Matoba S; Tatsumi T; Keira N; Kawahara A; Akashi K; Kobara M; Asayama J; Nakagawa M
    Circulation; 1999 Feb; 99(6):817-22. PubMed ID: 9989969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
    Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
    Heitzer T; Ollmann I; Köke K; Meinertz T; Munzel T
    Circulation; 2003 Aug; 108(5):536-41. PubMed ID: 12874186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin modulation of an endothelial nitric oxide component present in the alpha2- and beta-adrenergic responses in human forearm.
    Lembo G; Iaccarino G; Vecchione C; Barbato E; Izzo R; Fontana D; Trimarco B
    J Clin Invest; 1997 Oct; 100(8):2007-14. PubMed ID: 9329964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of AT1 receptor blockade on endothelial function in essential hypertension.
    Klingbeil AU; John S; Schneider MP; Jacobi J; Handrock R; Schmieder RE
    Am J Hypertens; 2003 Feb; 16(2):123-8. PubMed ID: 12559678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin C improves endothelial function of conduit arteries in patients with chronic heart failure.
    Hornig B; Arakawa N; Kohler C; Drexler H
    Circulation; 1998 Feb; 97(4):363-8. PubMed ID: 9468210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Role of endothelium-derived nitric oxide in sustained flow-dependent dilatation of human peripheral conduit arteries].
    Bellien J; Joannidès R; Iacob M; Eltchaninoff H; Thuillez Ch
    Arch Mal Coeur Vaiss; 2003; 96(7-8):738-41. PubMed ID: 12945214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism.
    Nikolaidis LA; Doverspike A; Huerbin R; Hentosz T; Shannon RP
    Circulation; 2002 Jun; 105(23):2785-90. PubMed ID: 12057995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bradykinin B2 receptor modulates renal prostaglandin E2 and nitric oxide.
    Siragy HM; Jaffa AA; Margolius HS
    Hypertension; 1997 Mar; 29(3):757-62. PubMed ID: 9052892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.